BioTelemetry (BEAT) was Initiated by Sidoti to “Buy”. Sidoti advised their investors in a research report released on Sep 13, 2016.
Many Wall Street Analysts have commented on BioTelemetry. Company shares were Reiterated by The Benchmark Company on Aug 3, 2016 to “Buy”, Firm has raised the Price Target to $ 25 from a previous price target of $20 .
On the company’s financial health, BioTelemetry reported $0.20 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.17. The company had revenue of $52.68 million for the quarter, compared to analysts expectations of $50.27 million. The company’s revenue was up 17.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.12 EPS.
BioTelemetry opened for trading at $17.64 and hit $17.93 on the upside on Monday, eventually ending the session at $17.92, with a gain of 1.64% or 0.29 points. The heightened volatility saw the trading volume jump to 355,123 shares. Company has a market cap of $502 M.
In a different news, on Sep 12, 2016, Daniel Wisniewski (SVP – Business Operations) sold 2,005 shares at $18.06 per share price. According to the SEC, on Sep 12, 2016, George Hrenko (SVP – Human Resources) sold 3,491 shares at $18.06 per share price. On Sep 12, 2016, Fred Broadway (SVP – Sales Marketing) sold 2,837 shares at $18.06 per share price, according to the Form-4 filing with the securities and exchange commission.